Histrelin
Vantas · Supprelin LA
Half-life
360 days
Time to Peak
7 days
Steady State
~1800 days
Bioavailability
100%
Dose Range
50–50 mg
Frequency
every 12 months
Overview
GnRH agonist delivered as a 12-month subcutaneous implant (small flexible rod inserted in the inner upper arm). Supprelin LA is specifically indicated for central precocious puberty; Vantas for advanced prostate cancer. Both contain 50 mg histrelin in a hydrogel reservoir that provides continuous release for 12 months. Requires minor surgical procedure for insertion and removal.
Mechanism of Action
Synthetic GnRH agonist. Hydrogel implant provides continuous release for 12 months, causing sustained pituitary GnRH receptor downregulation and gonadal suppression.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Subcutaneous (SubQ) | 50–50 mg | 360 days | 7 days | every 12 months |
Used in Regimens
Histrelin is not currently part of any catalog regimen.
Data Sources
- FDA Label Supprelin LA (histrelin acetate) FDA Prescribing Information
- FDA Label Vantas (histrelin acetate) FDA Prescribing Information
Related Tools
Track Histrelin with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.